Active Biotech AB Interim Report January - March 2013

(Thomson Reuters ONE) -


Laquinimod
· first patient enrolled in CONCERTO, the third Phase III placebo-controlled
study for the treatment of
relapsing-remitting multiple sclerosis
· data presented at AAN showed reduced disability progression for multiple
sclerosis patients who commenced
early treatment with laquinimod compared with delayed treatment

Tasquinimod
· the Phase III study is proceeding according to plan

ANYARA
· Phase II/III study in renal cell cancer concluded
· Results presented:
   - study did not achieve primary clinical endpoint
   - doubling of progression-free survival and overall survival in 25 percent of
patients
   - planning of the continued clinical development ongoing

57-57 (paquinimod)
· clinical trial in systemic sclerosis concluded, evaluation underway

ISI
· focus on submission of patents

Other information
· Active Biotech raised SEK 270 M through a directed share issue to Investor

        Jan - Mar Jan - Dec

 (SEK M) 2013 2012 2012
------------------------------------------------------------
*      Net sales   2.4    2.6 227.9

*      Operating loss  -77.0 -100.7 -163.2

*      Net loss -78.0 -99.0 -175.0

*      Earnings per share (SEK)
-1.10 -1.44 -2.54




For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund
Tel: 046 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com

Active Biotech AB : Interim Report January - March 2013:
http://hugin.info/1002/R/1695994/558366.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE
[HUG#1695994]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 25.04.2013 - 08:31 Uhr
Sprache: Deutsch
News-ID 252770
Anzahl Zeichen: 2688

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 114 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim Report January - March 2013"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech